NCT04994327

Brief Summary

This is a multicenter study testing the effect of bread containing beta-glucan on glycemic control in participants with intermediate hyperglycemia. The main hypothesis of the study is that bread enriched with beta-glucan will have a positive effect on blood glucose control (HbA1c) in persons with intermediate hyperglycemia. Bread (intervention and control) will be produced by Nofima (Ås, Norway) using food-grade beta-glucan from oat and barley and shipped to the study centers (Bergen (N), Gothenburg (S), Paderborn, and Leipzig (D)) and there distributed for free to the participants of the study. The study will last for 16 weeks with measurements at baseline, after 8 weeks and after 16 weeks. Blood and urine samples will be taken, anthropometry and body composition measured, and questionnaires on health status and socio-economic status, physical activity, nicotine use, alcohol habits, chronotype, quality of life, and consumer acceptance of the study bread will be filled in.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
155

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 7, 2021

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 7, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 6, 2021

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2023

Completed
Last Updated

December 4, 2023

Status Verified

December 1, 2023

Enrollment Period

2.4 years

First QC Date

July 7, 2021

Last Update Submit

December 1, 2023

Conditions

Keywords

beta-glucanhyperglycemiapre-diabetes

Outcome Measures

Primary Outcomes (1)

  • Glycemic control

    Measurement of HbA1c

    16 weeks

Secondary Outcomes (8)

  • fasting capillary blood glucose

    16 weeks

  • Body weight

    16 weeks

  • Lipids

    16 weeks

  • Consumer acceptance

    8 weeks

  • Liver enzymes

    16 weeks

  • +3 more secondary outcomes

Study Arms (2)

Beta-glucan bread

EXPERIMENTAL

Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks

Other: Beta-glucan bread

Control bread

PLACEBO COMPARATOR

Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks

Other: Beta-glucan bread

Interventions

Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks

Beta-glucan breadControl bread

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HbA1c 35-50 mmol/mol
  • BMI ≥ 27 m2/kg
  • regular bread eaters
  • freezing capacity of at least 2 bread

You may not qualify if:

  • chronic diseases like T2DM, CVD, cancer (within the last three years)
  • unknown or untreated hypertension \>160/100 mmHg
  • celiac diseases, intolerance, or allergies for nuts, milk, eggs, wheat, mustard, seeds
  • use of anti-diabetic drugs
  • pregnancy and breastfeeding
  • patients planned to have or had a bariatric surgery
  • alcohol abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Bergen

Bergen, 5021, Norway

Location

Related Publications (2)

  • Hjorth T, Schadow A, Revheim I, Spielau U, Meyer K, Rieder A, Varela P, Ballance S, Koerner A, Landberg R, Buyken AE, Dierkes J, Rosendahl-Riise H. Effectiveness of regular oat beta-glucan-enriched bread compared with whole-grain wheat bread on long-term glycemic control in adults at risk of type 2 diabetes: a randomized controlled trial. Am J Clin Nutr. 2025 Sep;122(3):724-732. doi: 10.1016/j.ajcnut.2025.06.018. Epub 2025 Jun 24.

  • Hjorth T, Schadow A, Revheim I, Spielau U, Thomassen LM, Meyer K, Piotrowski K, Rosendahl-Riise H, Rieder A, Varela P, Lysne V, Ballance S, Koerner A, Landberg R, Buyken A, Dierkes J. Sixteen-week multicentre randomised controlled trial to study the effect of the consumption of an oat beta-glucan-enriched bread versus a whole-grain wheat bread on glycaemic control among persons with pre-diabetes: a study protocol of the CarbHealth study. BMJ Open. 2022 Aug 23;12(8):e062066. doi: 10.1136/bmjopen-2022-062066.

MeSH Terms

Conditions

HyperglycemiaPrediabetic StateGlucose Intolerance

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesDiabetes MellitusEndocrine System Diseases

Study Officials

  • Jutta Dierkes, PhD

    University of Bergen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double-blinded
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Multicenter
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 7, 2021

First Posted

August 6, 2021

Study Start

May 7, 2021

Primary Completion

September 30, 2023

Study Completion

September 30, 2023

Last Updated

December 4, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations